Brain Balance: How Understanding Excitability Asymmetry Could Revolutionize Multiple Sclerosis Treatment
"New research reveals the potential of brain excitability as a key biomarker in multiple sclerosis, offering hope for more targeted and effective therapies."
Multiple sclerosis (MS) is a complex neurological condition affecting millions worldwide. It is characterized by the immune system attacking the protective myelin sheath around nerve fibers, leading to a range of physical and cognitive symptoms. Managing MS effectively requires a deep understanding of its underlying mechanisms, and recent research is shedding light on a promising new area: brain excitability.
Traditionally, MS research has focused on structural changes in the brain, such as lesions detected through MRI. While valuable, these structural insights don't fully explain the variability in symptoms and disease progression among individuals. Scientists are now exploring the functional aspects of the brain, particularly how nerve cells (neurons) communicate and respond to stimuli. This has led to the concept of brain excitability – the ease with which neurons fire – and how imbalances in this excitability might contribute to MS.
A groundbreaking study by Chaves et al. delves into the idea of brain excitability asymmetry in MS patients. This asymmetry refers to the differences in excitability between the left and right hemispheres of the brain. The study reveals that this asymmetry is not just a random occurrence but could be a critical biomarker, offering new avenues for diagnosis, treatment monitoring, and personalized therapeutic strategies in MS.
Excitability Across MS
Multiple sclerosis is an idiopathic inflammatory disorder of the central nervous system characterized by demyelination of white matter throughout the brain and spinal cord. The cited research notes that demyelination can be observed even early in the disease. In a longitudinal study, motor cortex excitability was examined over one year in 25 patients with progressive forms of MS using transcranial magnetic stimulation, including resting and other TMS parameters.
From Uncertainty to Progress
Multiple sclerosis was historically regarded as complex, indecipherable, and poorly understood, particularly regarding its cause. A review titled "Multiple sclerosis—a quiet revolution" presents an emphatically positive view of progress in understanding and treating the disease over several decades, especially during the preceding 20 years. Historical accounts trace MS research from its initial recognition in the 19th century through important discoveries, relapse treatments, and influential individuals.
What is Brain Excitability Asymmetry and Why Does It Matter in MS?
Brain excitability refers to the readiness of neurons to fire in response to stimulation. This process is crucial for all brain functions, from motor control to cognitive processing. In a healthy brain, there is a balance between excitatory and inhibitory signals, ensuring that neural activity is regulated and efficient. However, in neurological conditions like MS, this balance can be disrupted, leading to areas of hyperexcitability (overactive neurons) or hypoexcitability (underactive neurons).
- Objective and Subjective Symptoms: The study found that the severity of MS-related physical symptoms, such as walking speed and dexterity, as well as cognitive functions, correlates with the degree of brain excitability asymmetry.
- Neuroinflammation: Atypical brain excitability asymmetry in MS may indicate neuroinflammation-mediated hyperexcitability.
- Biomarker Potential: Shifting excitability asymmetry significantly predicted more severe physical MS symptoms and cognitive processing.
- Tracking Disease Progression: Monitoring brain excitability asymmetry could provide a way to track the progression of MS and assess the effectiveness of treatments.
Excitability as a Clinical Signal
Recent TMS research has examined corticospinal excitability and its relationship to disability and motor and cognitive function in MS. One study reports that a lower ratio of corticospinal excitation to inhibition predicts greater disability and poorer motor and cognitive function. Another reports statistically significant associations between interhemispheric asymmetry of corticospinal excitability and processing-speed impairment, with the strongest explanation involving lower excitability in the hemisphere corresponding to the clinically weaker upper extremity. Machine-learning work has also used walkway-sensor data from the Health Innovation Team in MS project in Newfoundland and Labrador, Canada, to study walking and balance difficulty.
Stimulation Evidence and Limits
The supplied evidence compares brain-stimulation approaches in different contexts rather than establishing a direct MS treatment ranking. A systematic review and meta-analysis of TMS and repetitive TMS for major depressive disorder reported a standardized mean difference of -0.3, with a 95% confidence interval from -0.82 to 0.23, and substantial heterogeneity: P < 0.001 and I-squared = 81.9%. A 2025 article frames electric versus magnetic stimulation within MS, a chronic neuroinflammatory and neurodegenerative disorder marked by demyelinating plaques in the brain and spinal cord that can produce physical and cognitive disabilities.
The Future of MS Treatment: Personalized Approaches Based on Brain Excitability
The findings of this study open new doors for personalized MS treatment. By understanding an individual’s unique pattern of brain excitability asymmetry, clinicians can potentially tailor therapeutic interventions to address the specific imbalances present. This could involve using targeted therapies to reduce hyperexcitability in one hemisphere or enhance activity in another, ultimately leading to improved symptom management and a better quality of life for those living with MS.
Modeling Network Severity
A 2026 preprint, "Brain Network Excitability Predicts Clinical Severity in MS," applies personalized computational brain modeling to reconstruct excitability-related metrics. The modeled measures include synaptic velocity and background activity in different neuronal populations. The authors hypothesize that these excitability metrics are altered by MS pathophysiology, using both healthy controls and MS patients in the modeling framework.
Toward Earlier, Personalized Care
Recent reviews describe MS as an autoimmune disease of the central nervous system affecting the brain, optic nerves, and spinal cord, with inflammation and demyelination among its hallmark effects. Diagnosis and treatment remain evolving challenges, and the 2024 revision of the McDonald criteria aims to support earlier, more accurate, and biologically informed diagnosis. The cited updates expand dissemination in space to include the optic nerve and integrate relapsing and other disease features. A discussion of brain excitability asymmetry presents personalized therapies as a possible route to improved patient outcomes, although that possibility remains prospective.
Symptoms Beyond Movement
MS can cause sensory and motor dysfunction, cognitive impairment, mood disorder, and fatigue. These symptoms can substantially affect quality of life. The cited editorial states that such complaints are mostly assessed clinically or with scales, questionnaires, and test batteries, and that they cannot always be completely or partially relieved. This creates a broader clinical challenge for evaluating disease impact beyond a single measure of corticospinal excitability.